The actin-binding protein ezrin is associated with cellular shape changes, motility, tumor invasion, and lymphocyte activation. We have earlier shown that ezrin immunoreactivity (IR) is faintly present in normal astrocytes but increased in malignant human astrogliomas. We studied the role of ezrin in astrocyte activation, applying immunostaining on serial paraffin sections from human autopsied brain tissues (51 cases). Cerebral HIV infection was chosen as a model displaying consistent exemplary astrocyte activation. Semiquantitative ezrin-IR was compared with the common glial markers GFAP, ferritin, and HLA-DR in relation to clinical and morphologic criteria of HIV encephalopathy. In all cases with HIV infection, GFAP-, HLA-DR-, and ferritin-IR were elevated in comparison to normal brain tissues. In contrast, high ezrin-IR in HIV infection strictly correlated with additional HIV encephalopathy. HIV encephalopathy with particularly high ezrin-IR was correlated with neuronal apoptosis (TUNEL). Combined ezrin-IR and GFAP-IR thus reveals 2 distinct states of astrocytic activation. Normal ezrin-IR, when paralleled by upregulated GFAP, reflects astroglial activation not associated with neuronal apoptosis. High ezrin-IR indicates specific astrocyte stressors related to cellular damage within the central nervous system. Ezrin-IR might also provide a diagnostic tool for the classification of HIV encephalopathy.
INTRODUCTION
The actin-binding protein ezrin is a member of the ERM family (ezrin, radixin, and moesin) sharing an extensive sequence homology of the aminoterminal domain with the erythrocyte membrane-cytoskeleton linker protein band 4.1 (1) . Ezrin, the main ERM representative, is found underneath the plasma membrane in cell surface structures such as microvilli, membrane ruffles, and cell-to-cell contact sites (2) (3) (4) (5) . This protein represents a link between the actin cytoskeleton and various membrane-bound molecules (6) , mostly cell adhesion molecules such as ICAM-1, ICAM-2, or CD44 (5, (7) (8) (9) . The presence of ezrin in the brain was previously established by Western blot (10) . Double-labeling studies in rat and mouse found an almost exclusive restriction of ezrin to ependymal cells and astrocytes (preferentially to their fine peripheral processes) and an absence in microglia (11) . Recent studies localized low-level ezrin immunoreactivity (IR) in normal human astrocytes (12, 13) . In human astroglial tumors, the intensity of their ezrin immunostaining was highly correlated with malignancy (12) . However, high ezrin-IR was also observed in nontumor astrocytes in the glioma environment (12) . Because these astrocytes are activated, this led to the hypothesis that increased ezrin expression might be generally related to glial activation. The present study aimed at systematically investigating the possibility of ezrin upregulation in relation to astroglial activation, independent of tumors.
The role of ezrin in the formation of immunologic synapses and activation of T cells is well established (14) . In particular, during lymphocyte activation, ezrin may play a major role in inducing the conformational changes involved in CD43 complexes (15) and in inducing apoptosis of targeted cells (16) . Migration and homing of activated lymphocytes is linked to the interaction of ezrin with the CD44 complex (17, 18) . Ezrin might play an analogous role in astrocytes, which represent immunocompetent cells of the central nervous system (CNS) (19) (20) (21) . Thus, astrocytes in parallel to some lymphocyte functions may play a major role in the regulation of the immune response in the CNS by inducing and maintaining a Th2-type response in the brain (20) . Activated astrocytes are capable of phagocytosis and antigen presentation (20) and inducing apoptosis in targeted cells (21) . Similarly, their reaction to chemokines and cytokines parallels aspects of lymphocyte activation (19) . Astrocyte activation is accompanied by alterations of cell shape, including an increased cytoplasm volume and extended filopodia (22, 23) , which may be related to ezrin function (11, 24) . Because exemplary astrocyte activation is consistently found in advanced stages of cerebral HIV infection (25, 26) , this disease provides a suitable model to investigate ezrin in astrocyte activation. We studied ezrin-IR in the brains from HIV-infected patients in comparison with GFAP, HLA-DR, and ferritin, established markers of glial activation that have been described in HIV infection of the CNS (27) (28) (29) . The HIV cases presently studied were subdivided into cerebral HIV infection with or without encephalopathy correlating to both clinical neurology and neuropathology. We show by semiquantitative evaluation that activated astrocytes may display increased ezrin-IR. Specifically, combined labeling for ezrin and established activation markers reveal 2 distinct states of astrocytic activation. In HIV infection without encephalopathy, astrocytic IR was increased for the reference markers but normal for ezrin. Increased astrocytic ezrin-IR was strictly related to HIV encephalopathy and additionally correlated with neuronal apoptosis. Ezrin-immunolabeling may potentially provide an easily applicable tool facilitating the still difficult neuropathologic classification of HIV-associated CNS damage in autopsy tissues (30) (31) (32) (33) .
MATERIALS AND METHODS

Cases
We performed immunocytochemistry on formalin-fixed, paraffin-embedded human brain tissues from autopsies without known CNS disease or hypoxia (10 normal control cases), 17 cases of HIV infection without neurologic deficits or obvious signs of encephalopathy, and 24 cases of patients with HIV encephalopathy. Extended hypoxia or HIV-independent neurodegeneration were considered as exclusion criteria. To obtain consistent results for immunocytochemistry and terminal transferase UDP-nick-end-labeling (TUNEL) technique (34) (35) (36) (37) (38) , strict criteria were applied for postmortem delay (less than 48 hours), fixation, and formalin storage times (4 weeks to 6 months) of autopsy tissues. The control cases comprised 8 male patients and 2 females with a mean age of 55 years. The group of HIV-infected patients without obvious encephalopathy included 16 males and one female; 12 patients were stage III HIV-1-associated disease according to the Centers for Disease Control and Prevention (CDC) and 5 patients were stage IV disease (39) (40) (41) (42) . The group of HIV-infected patients with encephalopathy contained 21 males and 3 females. Stage III disease was present in 2 cases and all other 22 cases had stage IV disease. The mean age was 41 years in both groups. None of the patients had been treated with highly active antiretroviral therapy (HAART).
Our definition of HIV encephalopathy is contained in but not identical to the conventional, clinical diagnosis of HIV encephalopathy. In addition to the diagnosis given by the clinicians, the ''HIV encephalopathy'' cases in our study had to meet histopathologic criteria with typical opaque periodic acid-Schiff (PAS)-positive HIV macrophages in the brain as a minimum requirement (43) (44) (45) . The cases displayed a history of systematic rather than focal neurology such as cognitive, behavioral, or systematic gait disorders, including parkinsonism-like features (46) . With regard to neuropathology, the selected cases demonstrated mostly diffuse tissue alterations. The presence of focal lesions could not be entirely avoided for reasons of group size, but they had to be small (up to 1 cm in diameter) and distant from the areas tested for this study. Some cases presently classified as ''encephalopathy'' would correspond to the diagnosis of encephalitis (47) . However, because the morphologic findings were not congruent with the current definition of encephalitis (multinucleated giant cells, microglia nodules, and focal lesions resulting from opportunistic infections) in a number of cases, the original classification of encephalopathy was applied. The cases were randomly selected and 3 regions were used for this study: cortex (mostly frontal), basal ganglia, and midbrain or pons. Diagnoses based on the evaluation of 6 to 12 sections were independently obtained by 2 observers. In selected samples from 6 cases with less than 16-hour postmortem delay of fixation, the presence of HIV virus in PAS-positive macrophages was confirmed by immunocytochemistry for HIV p24. The presence of opportunistic infections was assessed morphologically by immunochemistry, in situ hybridization, and/or polymerase chain reaction (PCR) of DNA extracted from paraffin sections (48) . EpsteinBarr virus (EBV), cytomegalovirus (CMV), and herpes simplex virus (HSV) were studied by PCR; EBV and JC virus by in situ hybridization; and CMV, EBV, HSV, and toxoplasmosis by immunoreaction.
Histology and Immunohistochemistry
Five-micrometer-thick serial sections were cut from paraffin-embedded tissue blocks and processed for staining with hematoxylin and eosin (H&E), PAS, and for immunocytochemistry, which was developed by applying the avidin-biotinperoxidase complex (ABC; Vector Laboratories, Burlingame, CA). Primary antibodies were applied at a concentration of 5 to 25 mg/mL for 1 to 12 hours. These were monoclonal anti-ezrin (3C12; Sigma, Deisenhofen, Germany) (10, 49) , which is only moderately sensitive to fixation artifacts or autolysis (12) , polyclonal anti-GFAP (Dako Diagnostika, Hamburg, Germany), antiferritin (Dako) and monoclonal anti-HLA-DR, anti-CD3, anti-CD20, anti-HIV p24, anti-LCA, and anti-HSV, anti-CMV, anti-EBV, and antitoxoplasma (all from Dako). The antibodies to CD3, CD20, LCA, GFAP, and HLA-DR required pretreatment by microwave heating at 600 W for 2 3 5 minutes, in 10 mM sodium citrate, pH 6.2.
Biotinylated, preadsorbed secondary antibodies (sheep antimouse; Amersham, Freiburg, Germany) and swine antirabbit (Dako) were used at a concentration of 10 mg/mL. Diaminobenzidine (0.05%, DAB, Sigma) in 0.02% H 2 O 2 /phosphate-buffered saline (PBS) served as chromogen. Counterstaining was performed with hematoxylin (Harris, 7 g/L). Nonfat dry milk (10%) and bovine serum albumin (10%) in PBS were used for blocking of nonspecific binding sites. Endogenous peroxidase was inactivated by immersion in PBS containing 1% H 2 O 2 for 10 to 20 minutes. Cell death (apoptosis) was determined using a modified TUNEL method applying an antidigoxigenin-peroxidase system (Oncor, Boehringer Mannheim, Germany) on sections of paraffinembedded tissues (34) .
Only areas without focal lesions were evaluated. Immunostaining was scored without knowledge of the diagnosis on 5-mm-thick sections at a magnification of 203 using a graded ocular lens (10 3 10 squares, corresponding to 500 3 500 mm at 20 3 magnification; Carl Zeiss, Oberkochen, Germany). As a positive control for TUNEL staining, autopsy tissue containing a highly malignant B-cell lymphoma with an established frequency of apoptotic cells was included in each staining series. Samples of positively stained sections were validated by chromatin appearance in semithin sections (34) .
The scoring system for semiquantitative evaluation of immunostaining is based on a combination of quantitative and qualitative criteria (12) . Possible variations in staining intensity between staining batches (up to 20 slides each) were accounted for by adding the same positive standard control to each batch. For staining consistency, sections from different brain areas of a given case were included in one staining batch and serial sections of the same area in different batches. Staining intensity was estimated at 203 magnification as described previously. Score values between zero (no staining) and 3 (heavy staining in more than 40% of the astrocytes) were accorded, as described in the legend to Figure 2 . For statistical analysis, the univariate x 2 test (x 2 ) and the corrected Pearson contingency coefficient (50, 51) for nonparametric correlation were applied.
RESULTS
HIV Infection: Histopathologic Diagnosis and Classification
The brains studied were distributed into 3 major groups: In normal brains from 10 autopsies without known CNS disease, no hypoxic damage, signs of neurodegenerative disease, or inflammation were detected by histology. Seventeen cases with HIV infection were grouped as HIV infection without encephalopathy. Four of them displayed opportunistic infections (13 CMV, 23 EBV, 13 toxoplasmosis, 13 CNS lymphoma in an EBV-positive case, which coincided with a stage IV HIV-associated disease). Despite opportunistic infections, these cases were classified as HIV infection without encephalopathy; because the infections were found only postmortem, none of the cases had been clinically diagnosed as HIV encephalopathy, and PAS-positive macrophages were absent. The twenty-four cases with HIV-associated neurologic symptoms and the neuropathologic diagnosis of HIV encephalopathy displayed at least considerable numbers of typical opaque PAS-positive, HIV-associated macrophages and, in some cases, multinucleated giant cells and gliosis. In selected cases (n = 6) with particularly short postmortem delay (below 16 hours), presence of HIV antigen in these macrophages was confirmed by immunochemistry for HIV p24; no HIV-IR was found outside PAS-positive macrophages (not shown). Twenty of the 24 cases had additional opportunistic infections (Table 1; 103 EBV, 63 CMV, 23 toxoplasmosis, 23 PML). In one case displaying EBV-positive PCR, small foci of secondary CNS lymphoma were found. Two other cases with small lymphoma infiltrates were EBV-negative, and in one case, EBV and CMV were discovered. Focal intense gliosis, slight demyelination, and mononuclear infiltration of the brain were present in 6 cases. Ezrin-IR was slightly stronger in the immediate surroundings of lesions, inflammatory changes, or tumors. Such focal alterations, however, were not included in the evaluation of ezrin-IR or other markers. None of the cases displayed predominant leukoencephalopathy.
Ezrin-IR, Glial Activation Markers, and Apoptosis in Normal Human Brain Tissues
Normal brain tissues from 10 autopsies (Fig. 1A-E) showed strong ezrin-IR in the apical pole of ependymal cells. We also found delicate staining mostly of peripheral processes in normal human astrocytes (mean staining score: 1.03), and faint staining within the soma and the nuclear membrane of some astrocytes in a few cases (Fig. 1B) . Positive staining with anti-ezrin was seen in a substantial number of cortical and white matter astrocytes, but not all astrocytes were immunoreactive. Ezrin-IR was preferentially located in the molecular layer of the cortex, in deeper cortical areas adjacent to the white matter, and in periventricular white matter but was entirely absent in microglia, oligodendrocytes, and neurons (not shown). There was no indication of glial activation in normal brain tissues. Most sections from normal brain tissues were entirely negative for HLA-DR (mean staining score: 0.05) and ferritin (0.03) (Fig. 1D, E ), apart from rare single cells, mostly in periventricular areas of the white matter. Delicate GFAP-IR (1.03) was visible in the cortical molecular layer of normal tissues, a few cells of the deeper cortical layers (Fig. 1C) , a substantial number of white matter glia, particularly perivascular astrocytes, subependymal astrocytes, and the ependymal cells. Apoptosis was entirely absent (Fig. 1A) .
Comparison of Glial Activation Markers and Ezrin-IR in HIV Infection
Brain tissues from the 17 cases of HIV infection without encephalopathy (Fig. 1F-J) showed a clear increase in GFAP-IR, HLA-DR-IR and ferritin-IR (Fig. 1H-J) when compared with normal tissues. This effect was pronounced for GFAP-IR (mean staining score: 2.64) and ferritin-IR (mean staining score: 2.09) ( Table 2 ; Fig. 2A ). GFAP-IR was almost evenly distributed in cortical and white matter astrocytes, with particularly strong IR in perivascular astrocytes of the periventricular regions. Ferritin-IR appeared mostly in white matter microglial cells without significant staining of oligodendrocytes or astrocytes. Cortical areas showed only single immunopositive cells. HLA-DR-IR, in contrast, was more evenly distributed with stained cells in both white matter and cortical areas. Positive cells were mostly astrocytes and some microglial cells. The pattern and intensity of ezrin-IR, however, did not significantly differ from normal tissues (mean staining score: 1.09) ( Fig. 1G; Table 2A , B) in the HIV cases without encephalopathy. All brain tissues from the 24 cases of HIV infection with encephalopathy ( Fig. 1K-O (Table 1) and was assessed only in extrafocal areas. As a key finding, the correlation between increased ezrin-IR and HIV encephalopathy was highly significant (p , 0.0001) when compared within all cases with HIV infection. Similarly, when scored for GFAP, HLA-DR, and ferritin staining, cases with HIV encephalopathy (Fig. 1M-O) showed also strongly and significantly elevated values (mean staining scores for GFAP: 2.95, HLA-DR: 2.61, ferritin: 2.52) (Table 2A, B; Fig. 2A) . The difference in mean staining scores between cases with and without HIV encephalopathy was pronounced for ezrin-IR (mean staining score: 1.04), but smaller for GFAP (score: 0.31), HLA-DR (score: 0.29), and ferritin IR (score: 0.38). In the overall comparison ( Fig. 2A) , ezrin-IR displayed a pronounced difference in staining intensity and pattern between cases with and without HIV encephalopathy, whereas there was no significant difference between normal controls and cases without HIV encephalopathy. The relation between groups was different for GFAP, HLA-DR, and ferritin IR. Differences were less pronounced but still significant in both ) and the corrected Pearson contingency coefficient (cc) for nonparametric correlation were applied. Score values were defined as described for Figure 2. (A) IR-scores for glial activation markers, including ezrin. The scores of the individual staining methods are given as the range of obtained results in 0.5-increments and as the mean score values. The intercase variability for a given staining is expressed as the standard deviation (SD ''inter''). The variability between the different brain regions within a given case was low, and in many cases, all regions were accorded the same value. The mean SD between regions (SD ''intra''), although merely from 3 to 4 regions in a single case, was often only half of that for intercase variability. comparisons such as normal controls versus HIV infection without encephalopathy and HIV infection without versus with encephalopathy (Table 2B) . Correspondingly, the increased ezrin-IR in HIV infection was strictly dependent on the presence of HIV encephalopathy (correlation coefficient 92%), whereas increases in HLA-DR or ferritin-IR were slightly correlated with both HIV infection and HIV encephalopathy (Table 2B) . Because these correlations are based on the pooled mean values, the possible relevance of combined staining for the astrocytic activation marker GFAP and ezrin was further analyzed at the single case level (Fig. 2B) : all normal control cases exhibited low staining with both markers. In all HIV infections, GFAP-IR was increased to varying degrees; however, increased ezrin-IR was only observed in simultaneous HIV encephalopathy (Figs. 1G, L, 2B) . The small overlap between the groups ( Fig. 2B ; Table 2 ) thus suggests that the combination of GFAP-IR and ezrin-IR may discriminate an additional state of glial activation.
Glial versus Neuronal Apoptosis in HIV Infection
Further investigation of these cases with HIV encephalopathy revealed 2 distinct subgroups differing in the type of cells undergoing apoptosis. One group displayed only glial apoptosis (n = 13); the second group revealed glial and neuronal apoptosis (n = 11). Most strikingly, within HIV encephalopathy, ezrin-IR was consistently stronger in cases displaying glial and neuronal apoptosis (correlation coefficient 100%) (Figs. 1K, 3 ; Table 2C ). Apoptosis was entirely absent in normal brain tissues (Fig. 1A) . HIV-infected brains without encephalopathy showed only low to moderate numbers of apoptotic cells (Table 2C) . They comprised glial cells, mostly microglia, some astrocytes, and oligodendrocytes primarily located in the central white matter. In some cases, glial satellite cells surrounding neurons were apoptotic (Fig. 1F) . Neuronal apoptosis was not detected in these cases. Two of the 17 cases without encephalopathy were negative for apoptosis. In HIV encephalopathy, apoptosis was a consistent finding and larger numbers of positive glial cells were present and distributed throughout gray and white matter. Glial apoptosis was found in astrocytes, oligodendroglia, and mainly in microglia. Neuronal apoptosis was observed in 11 of 24 cases. Apoptotic neurons were mostly large neurons of deeper cortical areas, the basal ganglia, and dopaminergic neurons of the substantia nigra (Fig. 1K ). All cases with neuronal apoptosis also displayed particularly strong ezrin-IR (Table 2C) . Ezrin exceeded a mean score of 2.0 always and only in those cases of HIV encephalopathy that were associated with neuronal apoptosis (p = 0.0001, contingency coefficient 100%) ( Fig. 3; Table 2C ). Because neurologic symptoms were inclusion criteria for HIV encephalopathy, all of these cases also had neurologic deficits, but the possible correlation between neuronal apoptosis and neurology could not be tested. Focal lesions or lymphoma were not correlated with neuronal apoptosis. There was also no significant correlation between neuronal apoptosis and GFAP-IR, HLA-DR-IR, or ferritin-IR (not shown). The extent of apoptosis was not influenced by the postmortem delay or the duration of formalin fixation, as indicated by the corresponding correlation diagrams ( Fig. 4; Table 3 ). In each section, white and gray matter was evaluated. Also included were pattern changes in relation to normal tissues. The scores are distributed as follows: When no staining was visible, a score of zero was accorded. A score of 0.5 was accorded for single, weakly positive cells among large numbers of entirely negative cells. A score of one was used for the delicate staining of astrocytic processes in normal tissues or for faint but consistent staining in a substantial number of cells. The scoring values were chosen to yield an average score value of one for ezrin-IR and GFAP-IR and a score of zero to 0.5 for ferritin and HLA-DR in normal tissues. A score of 2 denoted increased staining with partly diffuse cytoplasmic immunoreactivity in approximately 10% to 30% of the cells, and a score of 3 was used for most intense staining of more than 40% of the cells. Intermediate levels were scored 1.5 and 2.5, respectively. (B) The combined staining for GFAP and ezrin reveals that distinction between HIV without encephalopathy and HIV encephalopathy is present at the single case level; there was little overlap between the groups.
DISCUSSION
We have compared ezrin-IR with the glial activation markers GFAP, HLA-DR, and ferritin using a semiquantitative scoring system in 3 different groups of autopsy cases: normal, HIV infection without encephalopathy, and HIV infection with encephalopathy. Although GFAP-IR, HLA-DR-IR, and ferritin-IR were increased in all cases with HIV infection, ezrin-IR was strongly increased only and always when HIV infection was combined with encephalopathy. The correlation of ezrin-IR with HIV encephalopathy was statistically significant. In addition, apoptosis of neurons, which was seen only in a subset of HIV encephalopathy cases, correlated with particularly strong ezrin-IR.
Diagnostic Considerations
Because HIV encephalopathy has mainly been a clinical diagnosis based on neurologic symptoms, the autopsy findings aimed at confirming the clinical diagnosis. The neurologic symptoms of patients with AIDS, however, do not always permit the differentiation between HIV encephalopathy and cerebral opportunistic infections. This situation has been further complicated by the advent of HAART therapy. Although considerably increasing the survival time of patients, HAART appears to be less effective with regard to CNS pathology. Neither the frequency of HIV encephalopathy nor that of CNS opportunistic infections has decreased to the extent expected (52) . However, the morphology of HIV encephalopathy has become more inconspicuous, featuring mainly activated microglia and isolated macrophages without formation of giant cells (52) . Thus, the neuropathologic assessment of HIV encephalopathy has met with considerable difficulties. Morphologic alterations are highly variable, often lacking specificity or correlation with neurologic symptoms (29, 30, 32, (53) (54) (55) (56) . This may partly result from decomposition and inconsistent fixation of autopsy tissues mostly precluding RNA technology or the use of specific antibodies or from the complex interactions between HIV virions and opportunistic infections with varying distribution. The combination of clinical and morphologic data applied here to assess HIV encephalopathy in brain tissues from HIV-infected patients appeared reproducible and unequivocal. The finding of PAS-positive multinucleated giant cells and typical opaque PAS-positive macrophages (43) that contain HIV has emerged as one of the few morphologic criteria common to all cases of HIV encephalopathy (23, 30, 31, 43, 47, (57) (58) (59) (60) . This would also permit the inclusion of patients on HAART. Such patients, however, were excluded from the present study to obtain more homogeneous groups. The significant correlation between intense ezrin-IR and HIV encephalopathy, as defined here, indicates that HIV encephalopathy, but not cerebral HIV infection in general, is specifically detected by increased ezrin-IR. Practically, this increased ezrin-IR is easily distinguished from the very faint ezrin-IR in brains without HIV encephalopathy. Increase of the other glial markers detects HIV infection in general but cannot clearly discriminate additional HIV encephalopathy, particularly not without direct comparison (compare Figs. 1, 2) . Ezrin-immunolabeling might thus become instrumental in the diagnosis of HIV encephalopathy.
Ezrin as a Marker for a Novel State of Astrocyte Activation
Activation of microglia and astrocytes is a hallmark of HIV-associated CNS disease. Astrocyte activation in particular has been characterized by a variety of criteria such as morphology, proliferation, cytokine production, and the capacity for antigen presentation (25, (61) (62) (63) (64) . In the present study, activated astrocytes were defined by a set of morphologic criteria (enlarged nuclei displaying irregular chromatin, increased cytoplasm) and GFAP immunocytochemistry (increased cell number, thickened processes). Although not restricted to astrocytes, the immunologic facet of astrocyte activation is demonstrated by the increased capacity for antigen presentation. We have shown this aspect of glial activation in addition by staining for HLA-DR.
Because increased ezrin-IR was specific and selective for HIV encephalopathy but not for HIV infection, increased ezrin-IR may define a specific state of astroglial activation. This state is contained in but not identical to astrocytic activation as diagnosed by the conventional markers, which are also increased in HIV infection without encephalopathy. Astrocyte activation is, thus, not a homogeneous phenomenon but consists of distinct states, which have been shown here to be linked to distinct changes of the CNS environment. Interestingly, increased ezrin-IR also correlated with apoptosis of neurons (but not of glial cells), indicating that this specific astrocytic activation state is linked to neuronal damage, a key finding of this study. For the detection of apoptosis, a reproducible morphologic method was chosen to assess neurodegenerative changes in HIV encephalopathy (65) (66) (67) (68) . The cases could be grouped with regard to apoptotic cell type, which was either glial-only or glial and neuronal. A subgroup of the HIV encephalopathy cases displayed combined glial and neuronal apoptosis. Those cases also had a tendency toward more severe morphologic CNS damage and higher numbers of PASpositive macrophages. The neuronal damage was, however, not colocalized with or restricted to the areas with signs of the specific opportunistic infections present in most of these cases. We suggest, instead, that neuronal apoptosis may only mark the end point of CNS damage in encephalopathy, which displays a continuum of other structural changes not studied here such as glial involvement (69) and dendritic pathology.
Ezrin May Play a Specific Role in HIV Encephalopathy
Ezrin and neuronal apoptosis have been found to be linked statistically and might also be specifically associated. Interactions between ezrin and HIV might be involved in specific events during viral CNS infection. First, the presence of ezrin has been demonstrated in HIV virions (70) , which suggests a possible involvement of ezrin in virion assembly. Ezrin is also capable of interacting with the HIV envelope protein gp 120 (71) . Although astrocytes can be HIV-infected as well (28, 29) , ezrin upregulation would have to be expected not only in astrocytes, but also in microglia because microglia are the main target of cerebral HIV infection. Even when considering the microglial expression of an ezrin isoform not detectable by the antibody used (72) , HIV assembly itself would not be a likely candidate to induce ezrin upregulation. Second, the HIV protein gp 120 can lead to altered glutamate uptake by astrocytes and induction of neuronal apoptosis (64, 73, 74) . It is, thus, conceivable that the interaction between ezrin and HIV gp 120 (71) might be involved in neuronal apoptosis through increased glutamate toxicity. This is supported by the known role of ezrin in intracellular mediation of apoptosis and intercellular/transcellular induction of apoptosis. Thus, ezrin is involved in microvillar breakdown during early apoptosis of L929 mouse epithelial cells (75) . Ezrin can also interact with CD95, possibly inducing apoptosis in lymphocytes (16) , and may also be linked to apoptosis induction in neurons. Third, recent studies have indicated a further mechanism of ezrin-associated neuronal damage in HIV infection. Phosphorylated ezrin is a key mediator in CD95-triggered apoptosis in CD41 lymphocytes (76) (77) (78) . HIV gp120 leads to ezrin phosphorylation in both infected and noninfected CD41 lymphocytes, thereby increasing their susceptibility to CD95-mediated apoptosis (76) . It would be interesting to study the presence of comparable phenomena in astrocytes and neurons, because CD95-mediated apoptosis has been described for neurons as well (79, 80) . In parallel to the induction of CD95-dependent neuronal apoptosis in Alzheimer disease by amy- loid (81), ezrin might be a key player in gp120-associated killing of noninfected neurons in HIV encephalopathy. Altogether, ezrin-HIV interaction may operate through several mechanisms in neuronal apoptosis induction. However, late stages of HIV-associated CNS disease frequently display additional opportunistic infection, as presently confirmed. It is not possible, therefore, to differentiate specific HIV effects from potential effects of opportunistic infection on neuronal apoptosis. The wide range of opportunistic infections observed here does not allow for a statistical analysis of the individual infectious agents in relation to ezrin-IR, and the neuropathologic analysis would require unrealistically homogeneous patient groups. The heterogeneity of opportunistic infections may prove advantageous when the focus is shifted from the role of HIV to that of astrocytes, as demonstrated by the present confirmation of an astrocytic role in neuronal damage. Even then there is no indication from the evidence presented here that a single infectious agent in patients with HIV encephalopathy may have a specific role in neuronal apoptosis. Further work will be necessary to establish whether the astrocytic activation state observed here is specific for HIV encephalopathy. Alternatively, cumulative effects of various damaging processes, including HIV infection, associated gp 120 toxicity, and opportunistic infection, might cause the increase in ezrin. In this scenario, ezrin upregulation would mark an end point of astrocytic activation common to neurodegenerative disease in general.
In summary, we have demonstrated that increased ezrin-IR is linked to astrocytic activation in HIV encephalopathy but not in HIV infection without encephalopathy. The comparison with conventional glial activation markers indicates that astrocytic activation has to be redefined. The data suggest that ezrin may play a specific role in astrocyte activation in relation to neuronal apoptosis, at least in HIV encephalopathy. In addition, pending further validation, anti-ezrin may provide an easily applicable and more discerning tool than GFAP staining for the evaluation of astrocyte activation, which, in turn, may facilitate the neuropathologic classification of HIV encephalopathy.
